NASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis $3.91 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.83▼$4.1150-Day Range$3.16▼$4.8752-Week Range$2.20▼$5.14Volume216,517 shsAverage Volume474,284 shsMarket Capitalization$386.70 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AC Immune alerts: Email Address AC Immune MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside206.9% Upside$12.00 Price TargetShort InterestHealthy1.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.20) to $0.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 starsMedical Sector646th out of 936 stocksPharmaceutical Preparations Industry299th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days.Read more about AC Immune's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.67% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AC Immune has recently increased by 31.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACIU. Previous Next 1.9 News and Social Media Coverage News SentimentAC Immune has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for AC Immune this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.20) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AC Immune's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About AC Immune Stock (NASDAQ:ACIU)AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More ACIU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACIU Stock News HeadlinesJuly 25 at 8:54 AM | finanznachrichten.deAC Immune SA: AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's DiseaseJuly 25 at 8:54 AM | markets.businessinsider.comAC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s DiseaseJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 7:00 AM | globenewswire.comAC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's DiseaseMay 28, 2024 | globenewswire.comAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024May 21, 2024 | finance.yahoo.comIndividual investors own 24% of AC Immune SA (NASDAQ:ACIU) shares but private equity firms control 30% of the companyMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Strategic Partnerships and Promising Pipeline in AC Immune SAMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed: AC Immune’s Promising Alzheimer’s Vaccine and Strategic Takeda PartnershipJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 14, 2024 | ft.comTakeda Pharmaceuticals reaches $2bn deal to develop Alzheimer’s vaccineMay 13, 2024 | msn.comAlzheimer’s vaccine licensing deal boosts AC ImmuneMay 13, 2024 | finance.yahoo.comSector Update: Health Care Stocks Mixed Late AfternoonMay 13, 2024 | investorplace.comACIU Stock Earnings: AC Immune Misses EPS for Q1 2024May 13, 2024 | investorplace.comWhy Is AC Immune (ACIU) Stock Up 45% Today?May 13, 2024 | marketwatch.comAC Immunity Shares Soar on Exclusive License Deal with TakedaMay 13, 2024 | sfgate.comAC Immune: Q1 Earnings SnapshotMay 13, 2024 | finance.yahoo.comTakeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment CandidateMay 13, 2024 | globenewswire.comAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateSee More Headlines Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+206.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,410,000.00 Net MarginsN/A Pretax Margin-370.47% Return on Equity-38.44% Return on Assets-33.76% Debt Debt-to-Equity RatioN/A Current Ratio7.78 Quick Ratio7.78 Sales & Book Value Annual Sales$16.48 million Price / Sales23.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.84Miscellaneous Outstanding Shares98,900,000Free Float94,350,000Market Cap$386.70 million OptionableOptionable Beta1.27 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Andrea Pfeifer Ph.D. (Age 67)Co-Founder, CEO & Director Comp: $1.09MMr. Christopher Roberts (Age 34)CFO & VP of Finance Mr. Piergiorgio Donati (Age 53)Chief Technical Operations Officer Mr. Jean-Fabien Monin (Age 53)Chief Administrative Officer Mr. Howard Donovan (Age 48)Chief HR Officer Ms. Madiha Derouazi (Age 51)Chief Scientific Officer Dr. Gary Anthony Waanders Ph.D. (Age 60)Senior VP of Investor Relations & Corporate Communications Mr. Alexandre Caratsch (Age 58)General Counsel Mr. Julian SnowVP of U.S. Finance & Corporate DevelopmentDr. David T. HickmanHead of AD - SMEMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSSana BiotechnologyNASDAQ:SANANurix TherapeuticsNASDAQ:NRIXDay One BiopharmaceuticalsNASDAQ:DAWNANI PharmaceuticalsNASDAQ:ANIPView All CompetitorsInstitutional OwnershipAssenagon Asset Management S.A.Bought 328,312 shares on 7/18/2024Ownership: 0.445%Silverberg Bernstein Capital Management LLCBought 10,000 shares on 7/12/2024Ownership: 0.010%Redmile Group LLCBought 7,031 shares on 5/16/2024Ownership: 2.029%Lazard Asset Management LLCBought 10,260 shares on 5/15/2024Ownership: 0.010%Platinum Investment Management Ltd.Sold 420,559 shares on 5/14/2024Ownership: 1.107%View All Institutional Transactions ACIU Stock Analysis - Frequently Asked Questions How have ACIU shares performed this year? AC Immune's stock was trading at $5.00 at the start of the year. Since then, ACIU shares have decreased by 21.8% and is now trading at $3.91. View the best growth stocks for 2024 here. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06. What is Andrea Pfeifer's approval rating as AC Immune's CEO? 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did AC Immune IPO? AC Immune (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are AC Immune's major shareholders? AC Immune's top institutional shareholders include Assenagon Asset Management S.A. (0.44%), Silverberg Bernstein Capital Management LLC (0.01%) and Concourse Financial Group Securities Inc.. How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX). This page (NASDAQ:ACIU) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
